Implications of CD39 in immune-related diseases.

Jianrui Zeng, Zhaochen Ning, Yuzhong Wang, Huabao Xiong

International immunopharmacology 2020 Dec

filter terms:

Extracellular adenosine triphosphate (eATP) mediates pro-inflammatory responses by recruiting and activating inflammatory cells. CD39 can hydrolyze eATP into adenosine monophosphate (AMP), while CD73 can convert AMP into the immunosuppressive nucleoside adenosine (ADO). CD39 is a rate-limiting enzyme in this cascade, which is regarded as an immunological switch shifting the ATP-mediated pro-inflammatory environment to the ADO- mediated anti-inflammatory status. The CD39 expression can be detected in a wide spectrum of immunocytes, which is under the influence of environmental and genetic factors. It is increasingly suggested that, CD39 participates in some pathophysiological processes, like inflammatory bowel disease (IBD), sepsis, multiple sclerosis (MS), allergic diseases, ischemia-reperfusion (I/R) injury, systemic lupus erythematosus (SLE), diabetes and cancer. Here, we focus on the current understanding of CD39 in immunity, and comprehensively illustrate the diverse CD39 functions within a variety of disorders. Copyright © 2020 Elsevier B.V. All rights reserved.

Citation

Jianrui Zeng, Zhaochen Ning, Yuzhong Wang, Huabao Xiong. Implications of CD39 in immune-related diseases. International immunopharmacology. 2020 Dec;89(Pt A):107055